Vertex Pharmaceuticals
NEWS
It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
Today, on this 11th World Rare Disease Day, life science companies, organization and activists have come together to raise awareness about these diseases and the needs of therapies for patients.
Vertex Pharmaceuticals announced that Reshma Kewalramani will be the new chief medical officer and executive vice president, Global Medicines Development and Medical Affairs
Vertex Pharmaceuticals announced it is starting its first Phase III trial of VX-659, a triple combination of the VX-659, tezacaftor and ivacaftor for cystic fibrosis.
Vertex has declined to comment, but BioCentury received a copy of the letter the company sent to laboratories explaining.
The FDA approved Vertex’s Symdeko for cystic fibrosis in patients ages 12 and older with two copies of the F508del mutation.
Here is a look at a few important regulatory events scheduled for the month of February.
Vertex is keeping its promise of advancing triple combination treatments for patients with cystic fibrosis and investors are happy.
JOBS
IN THE PRESS